China Biopharmaceutical (01177): Second-generation flurbiprofen patch approved for marketing

^{Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group's subsidiary, Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide), has obtained approval from the China National Drug Administration (NMPA) for marketing of the following diseases and symptoms: osteoarthritis, periodontitis, tendon and tenosynovitis, peritenosynovitis, swelling and pain caused by lateral epicondylitis of humerus (tennis elbow), muscle pain, and trauma.} The product also received a 4-year NMPA data protection period, building a solid barrier to consolidate the Group's leading position in the market.

There are more than 200 million chronic pain patients in China, and the trend is getting younger. Osteoarthritis, sports injuries, and shoulder, neck and back pain are not only more common among middle-aged and elderly people, but the incidence rate is also increasing year by year among fitness people, outdoor sports enthusiasts, and sedentary office workers. Topical patches have become the preferred solution for pain management due to the advantages of topical administration and avoidance of gastrointestinal irritation. However, traditional gel patches have a heavy texture and come off easily when exposed to sweat, making it difficult to meet the actual needs of patients during exercise or daily activities, and there is an urgent need for a more complete solution.

As an upgraded product of flurbiprofen gel patch, the second-generation flurbiprofen patch uses a new hot melt adhesive transdermal technology to achieve a comprehensive upgrade in the three dimensions of material, process and structure. On the basis of continuing the exact analgesic efficacy of the original product, the clinical application scenarios of external patches have been further broadened, and they have the advantages of thinner patches, more stable application, faster effect, and freedom of movement.